Walden Biosciences
Dr. Nowacek joined ARCH in 2015. He focuses on identifying and evaluating new life sciences technologies and forming companies around them. He was a co-founder of and instrumental in the early development of HiberCell, ROME Therapeutics, and Walden Biosciences. He continues serving all as either a board member/observer or by supporting corporate development. Dr. Nowacek holds a B.S. in Biology and a B.S. in Psychology from the University of Indiana-Bloomington. He also holds an M.D. and Ph.D. from the University of Nebraska Medical Center and an M.B.A. from the University of Nebraska-Omaha. He subsequently completed a medical residency in pathology and post-doctoral research at The University of Chicago and Massachusetts General Hospital. He holds eight issued patents and applications for therapeutic and R&D applications and has over 25 peer-reviewed publications in the areas of oncology, neuroscience, virology, and antiretroviral therapeutic development.
This person is not in the org chart
This person is not in any offices
Walden Biosciences
Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives. Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need. Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.